Clinical Trials and Product Development - The company announced the discontinuation of three Phase 3 trials for its lead product candidate, posoleucel, after futility analyses indicated they were unlikely to meet primary endpoints[94]. - The company has paused the development of its investigational VST therapies, including ALVR106 and ALVR107, pending the outcome of the strategic alternatives review[96]. - The company has faced disruptions in clinical trials and operations due to the COVID-19 pandemic, which may continue to impact future development[107]. Financial Performance - The company reported a net loss of $30.3 million for the three months ended March 31, 2024, with an accumulated deficit of $686.5 million[101]. - The company has not generated any revenue from product sales and has incurred significant operating losses since inception[97]. - Research and development expenses decreased to $12.2 million for Q1 2024 from $30.7 million in Q1 2023, a reduction of $18.5 million due to the discontinuation of clinical trials and workforce reduction[124]. - General and administrative expenses were $10.7 million in Q1 2024, down from $12.5 million in Q1 2023, reflecting a decrease of $1.9 million primarily due to reduced personnel costs[125]. - Total operating expenses decreased to $32.3 million in Q1 2024 from $43.2 million in Q1 2023, a decline of $10.9 million[122]. - Net cash used in operating activities was $44.4 million for Q1 2024, compared to $32.1 million in Q1 2023, reflecting a significant increase in cash outflow[136]. Cash and Liquidity - As of March 31, 2024, the company had cash, cash equivalents, and short-term investments totaling $140.5 million, expected to fund operations for at least twelve months[107]. - Cash, cash equivalents, and short-term investments totaled $140.5 million as of March 31, 2024, enabling the company to fund operations for at least the next twelve months[129]. - The company has received net cash proceeds of approximately $156.3 million from preferred stock sales and $292.0 million from its IPO, supporting its liquidity[128]. Workforce and Restructuring - A workforce reduction plan was approved in January 2024, resulting in a reduction of approximately 95% of the workforce, aimed at capital preservation[95]. - Restructuring costs amounted to $9.5 million in Q1 2024, primarily related to severance and employee termination costs[126]. - The company expects to continue incurring costs related to evaluating strategic alternatives and operating as a public company, despite the workforce reduction[102]. Strategic Alternatives - The company plans to conduct a comprehensive review of strategic alternatives, including potential mergers, sales, or divestitures, to maximize stockholder value[95]. - Future funding requirements may increase significantly if the company resumes development of product candidates, depending on various factors including regulatory approvals and commercialization activities[132]. Accounting and Reporting - The company prepares its unaudited condensed consolidated financial statements in accordance with U.S. GAAP, requiring estimates and judgments that affect reported amounts of assets and liabilities[141]. - The company has elected to take advantage of the extended transition period for complying with new or revised accounting standards as an emerging growth company[142]. - The company will remain an emerging growth company until it has total annual gross revenues of at least $1.235 billion or the market value of its common shares held by non-affiliates exceeds $700 million[144]. - The company is classified as a "smaller reporting company," with a market value of stock held by non-affiliates less than $700 million and annual revenue below $100 million[145]. - As a smaller reporting company, the company may present only the two most recent fiscal years of audited financial statements in its Annual Report on Form 10-K[145]. - The company is not required to disclose quantitative and qualitative disclosures about market risk due to its status as a smaller reporting company[147]. - Recently issued accounting pronouncements that may impact the company's financial position are disclosed in Note 2 of the condensed consolidated financial statements[146].

Strategic Review and Business Operations - The company is undergoing a comprehensive review of strategic alternatives aimed at maximizing shareholder value, including potential mergers, sales, or divestitures, with no set timetable for completion [169]. - A workforce reduction of approximately 95% is expected to be completed by April 15, 2024, to reduce costs and preserve capital, with estimated restructuring charges of around $13 million [172]. - The company has discontinued three global Phase 3 studies of posoleucel and other clinical development programs as part of its strategic review [172]. - The strategic review process may incur substantial costs, including legal and accounting fees, which could decrease available cash for business operations [169]. - The company has not set a definitive course of action regarding its strategic review, and any potential transaction may not yield the anticipated benefits [171]. - The company may pursue dissolution and liquidation if a strategic transaction is not consummated, impacting cash available for distribution to shareholders [171]. Regulatory and Clinical Development Challenges - The majority of the company's product candidates are still in preclinical development, with no regulatory approvals obtained for any product candidates, including posoleucel and ALVR106 [175]. - The company anticipates significant costs associated with the commercialization of any approved product candidates, which may hinder profitability [175]. - The ability to successfully develop and commercialize product candidates is contingent upon various factors, including regulatory approvals and market acceptance [175]. - The regulatory approval process for the company's novel multi-VST-cell therapy is complex and may take longer than for other pharmaceutical products due to the lack of existing FDA-approved cell-based therapies for viral diseases [181]. - The company faces risks related to the unpredictability of clinical trial results, which could significantly harm its business and prospects if regulatory approval is not obtained [180]. - Disruptions at the FDA and other regulatory agencies due to funding shortages could hinder timely product development and approval, negatively impacting the company's operations [182]. - The company must navigate a rigorous regulatory landscape for gene and cell therapy, which is subject to frequent changes and heightened scrutiny [183]. - Clinical trials may experience delays due to various factors, including difficulties in recruiting suitable subjects and obtaining necessary regulatory approvals [189]. - The company relies on CROs and other vendors for clinical trial execution, which may impact the timely conduct of trials due to limited influence over their performance [192]. - The FDA may impose additional post-market requirements, such as Risk Evaluation and Mitigation Strategies, which could affect commercialization plans [187]. Financial Condition and Funding - The company incurred net losses of $190.4 million and $168.7 million for the years ended December 31, 2023 and 2022, respectively, with an accumulated deficit of $656.2 million as of December 31, 2023 [290]. - The company anticipates significant losses to continue for the foreseeable future as it progresses with research and development and seeks regulatory approvals for its product candidates [290]. - The company will need substantial additional funding to support the development and commercialization of its product candidates, which may be delayed or reduced if capital is not raised [295]. - The company believes its existing cash resources will fund operating expenses for at least twelve months following the issuance of financial statements, but this estimate may prove incorrect [298]. - The company had cash, cash equivalents, and short-term investments of $183.9 million as of December 31, 2023 [297]. Market and Competitive Landscape - The total addressable market opportunity for posoleucel will depend on acceptance by the medical community, patient access, drug pricing, and reimbursement, which may affect revenue and profitability [214]. - The company faces substantial competition from pharmaceutical and biotechnology enterprises, which may impact its commercial opportunities if competitors develop safer or more effective products [209]. - There are currently no FDA- or EMA-approved drugs for the company's indications, except for COVID-19, which may affect market entry and pricing strategies [210]. - The commercial success of the company's product candidates depends on significant market acceptance among healthcare providers and patients, influenced by factors such as efficacy, safety, and reimbursement availability [228]. Intellectual Property and Licensing - The company relies heavily on the BCM License for intellectual property, data, and know-how, which is critical for the commercialization of its product candidates [320]. - Disputes may arise regarding the scope of rights under licensing agreements, potentially impacting the company's ability to develop and commercialize products [321]. - The company has limited control over the patent application process and enforcement of intellectual property rights licensed from third parties, which may affect its competitive position [323]. - The company has filed multiple patent applications for its product candidates, but there is no assurance that these will result in issued patents or that they will be enforceable [336]. Compliance and Regulatory Risks - Compliance with healthcare laws and regulations may result in significant civil, criminal, and administrative penalties, including exclusion from government-funded healthcare programs [244]. - The company is subject to evolving compliance requirements that impose significant costs, including organizational changes and additional protection technologies [249]. - Regulatory authorities may impose sanctions for non-compliance, impacting business and financial condition [315]. - The company may face penalties or restrictions if it fails to comply with regulatory requirements, which could inhibit commercialization efforts [222]. Employee and Operational Risks - The company is highly dependent on key personnel, and any loss of these individuals could delay product development and harm business operations [252]. - The company had 112 employees as of December 31, 2023, and anticipates needing additional personnel for future growth and development [258]. - Changes in U.S. immigration laws could adversely affect the company's ability to hire skilled personnel, impacting its operations [254]. Stock and Market Performance - The trading price of the company's common stock is likely to be highly volatile, influenced by various factors including clinical trial results and regulatory decisions [357]. - The company has not maintained a minimum closing bid price of $1.00 per share for the last 30 consecutive business days, as notified by Nasdaq [360]. - The company has until August 7, 2024, to regain compliance with the Minimum Bid Price Requirement, which requires the closing bid price to be $1.00 or more for at least 10 consecutive business days [361].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against AlloVir, Inc. due to allegations of violations of federal securities laws related to misleading statements about the posoleucel Phase 3 studies [1][2]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses exceeding $25,000 in AlloVir stock or options between March 22, 2022, and December 21, 2023, to contact them for legal options [1]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [2]. Allegations Against AlloVir - The complaint alleges that AlloVir and its executives made false and misleading statements regarding the posoleucel Phase 3 studies, including: - The studies were unlikely to meet their primary endpoints [2]. - The likelihood of discontinuation of the posoleucel Phase 3 studies [2]. - Overstating the efficacy and commercial prospects of posoleucel [2]. - Public statements made by the company were materially false and misleading [2]. Stock Price Impact - Following the announcement on December 22, 2023, that AlloVir would discontinue the posoleucel Phase 3 studies due to efficacy concerns, the stock price fell by $1.57 per share, or 67.38%, closing at $0.76 per share [3]. Class Action Details - The lead plaintiff in a class action is the investor with the largest financial interest who directs the litigation on behalf of the class [3]. - Any member of the class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [3].

Group 1 - AlloVir, Inc. (ALVR) has shown a year-to-date return of approximately 4.4%, outperforming the Medical sector average return of about -0.9% [2][3] - The Zacks Consensus Estimate for ALVR's full-year earnings has increased by 57.9% in the past quarter, indicating improved analyst sentiment and a more positive earnings outlook [2] - AlloVir, Inc. currently holds a Zacks Rank of 2 (Buy), suggesting it is positioned to outperform the broader market in the near term [1][2] Group 2 - AlloVir, Inc. is part of the Medical - Drugs industry, which consists of 192 individual stocks and is currently ranked 94 in the Zacks Industry Rank [3] - The Medical - Drugs industry has experienced a year-to-date loss of about -0.9%, indicating that ALVR is performing better than its industry peers [3] - In comparison, Arcutis Biotherapeutics, Inc. (ARQT), another stock in the Medical sector, has achieved a year-to-date return of 64.1% and also holds a Zacks Rank of 2 (Buy) [2][3]

Core Viewpoint - AlloVir, Inc. (ALVR) has experienced a significant decline of 72.4% in its stock price over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to improved earnings expectations from analysts [1]. Group 1: Stock Performance and Technical Indicators - The stock has been under heavy selling pressure, leading to an RSI reading of 28.82, indicating it may be oversold and could bounce back towards its previous equilibrium [4]. - The Relative Strength Index (RSI) is a momentum oscillator that helps identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2]. Group 2: Earnings Estimates and Analyst Consensus - There is a strong consensus among sell-side analysts that ALVR will report better earnings than previously predicted, with a 59.1% increase in the consensus EPS estimate over the last 30 days [4]. - ALVR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a favorable outlook for a potential turnaround [5].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________to __________________ Commission File Number: 001-39409 ALLOVIR, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (S ...

Financial Performance - The company reported net losses of $45.3 million and $86.5 million for the three and six months ended June 30, 2023, respectively, with an accumulated deficit of $552.2 million as of the same date [91]. - The company has not generated any revenue from product sales and relies on equity and debt financing for operations [93]. - The company anticipates continued significant operating losses due to ongoing R&D activities, regulatory approvals, and expansion of manufacturing capabilities [92]. - The company anticipates significant future operating losses as it advances product candidates through clinical development and seeks regulatory approval [123]. - The company reported a net loss of $86.5 million for the six months ended June 30, 2023, partially offset by non-cash charges of $19.5 million [129]. Funding and Capital - The company has raised a total of $292.0 million from its IPO and $126.4 million from a securities purchase agreement in July 2022, with a recent public offering generating net proceeds of $70.2 million [88][90]. - The company has raised approximately $156.3 million from preferred stock sales and $292.0 million from common stock in its IPO, among other financing activities [120]. - The company expects to finance its cash needs through equity offerings, debt financings, and collaborations, which may dilute shareholder ownership [125][126]. - The company may need to delay or limit product development if unable to raise additional funds through equity or debt financings [126]. Research and Development - The lead product, posoleucel, is being studied in three ongoing Phase 3 trials, with data readouts expected in 2024, targeting six viruses [88]. - The company is developing additional investigational VST therapies, including ALVR106 for respiratory diseases and ALVR107 for hepatitis B, with ALVR107 expected to enter a POC study after posoleucel's Phase 3 studies [88]. - Research and development expenses increased to $34.8 million for the three months ended June 30, 2023, compared to $31.4 million for the same period in 2022, reflecting a $3.4 million increase [111]. - For the six months ended June 30, 2023, research and development expenses totaled $65.5 million, up from $60.4 million in the same period in 2022, marking a $5.1 million increase [116]. - The increase in research and development costs was primarily due to a $4.6 million rise in expenses related to the development of posoleucel, driven by clinical trial costs and manufacturing outsourcing [111]. - The company plans to increase research and development expenses significantly in the foreseeable future to support ongoing clinical trials and product development [102]. Cash and Investments - As of June 30, 2023, the company had cash, cash equivalents, and short-term investments of $246.5 million, expected to fund operations for at least twelve months [94]. - Cash, cash equivalents, and short-term investments were $246.5 million as of June 30, 2023, expected to fund operations for at least the next twelve months [122]. - Net cash used in operating activities was $59.2 million for the six months ended June 30, 2023, compared to $75.4 million for the same period in 2022, reflecting a decrease of $16.1 million [129][130]. - Net cash provided by investing activities was $79.6 million for the six months ended June 30, 2023, primarily due to investment maturities of $93.8 million [131]. - Net cash provided by financing activities was $70.5 million for the six months ended June 30, 2023, primarily from $70.2 million in net proceeds from the issuance of common stock [132]. - The company reported a net increase in cash, cash equivalents, and restricted cash of $90.9 million for the six months ended June 30, 2023 [128]. Operational Challenges - The company is assessing the impact of COVID-19 on its operations, which has previously caused delays in clinical trials [94][96]. - The company has entered into a relationship with ElevateBio for drug development and manufacturing services, with shared management roles [97]. - The change in net operating assets and liabilities for the six months ended June 30, 2023, was primarily due to an increase of $4.9 million in accounts payable and accrued expenses [129]. - The company has not experienced material changes to its contractual obligations during the six months ended June 30, 2023 [133]. - The company continues to rely on exemptions and reduced reporting requirements as an emerging growth company under the JOBS Act [135][136].

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements (unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) This section presents the unaudited condensed consolidated financial statements for Q1 2023, detailing a **net loss of $41.2 million** and **total assets of $244.0 million** [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Condensed Consolidated Balance Sheet Highlights (Unaudited) | Balance Sheet Items | March 31, 2023 (in thousands USD) | December 31, 2022 (in thousands USD) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $115,698 | $106,092 | | Short-term investments | $86,872 | $127,703 | | Total current assets | $212,275 | $243,052 | | **Total assets** | **$244,044** | **$277,079** | | **Liabilities & Stockholders' Equity** | | | | Total current liabilities | $24,959 | $24,338 | | Total liabilities | $50,512 | $52,560 | | Total stockholders' equity | $193,532 | $224,519 | | **Total liabilities and stockholders' equity** | **$244,044** | **$277,079** | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Statement of Operations Summary (Unaudited) | Metric | Three Months Ended March 31, 2023 (in thousands USD) | Three Months Ended March 31, 2022 (in thousands USD) | | :--- | :--- | :--- | | Research and development | $30,718 | $29,067 | | General and administrative | $12,513 | $14,126 | | **Loss from operations** | **$(43,231)** | **$(43,193)** | | Interest income | $1,325 | $148 | | **Net loss** | **$(41,183)** | **$(43,863)** | | **Net loss per share — basic and diluted** | **$(0.44)** | **$(0.69)** | [Condensed Consolidated Statements of Changes in Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders'%20Equity) - Total stockholders' equity decreased from **$224.5 million** at December 31, 2022, to **$193.5 million** at March 31, 2023, primarily driven by the **net loss of $41.2 million**, partially offset by **$10.0 million** in stock-based compensation[33](index=33&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash Flow Summary (Unaudited) | Cash Flow Activity | Three Months Ended March 31, 2023 (in thousands USD) | Three Months Ended March 31, 2022 (in thousands USD) | | :--- | :--- | :--- | | Net cash used in operating activities | $(32,118) | $(46,476) | | Net cash provided by (used in) investing activities | $41,724 | $(54,979) | | Net increase (decrease) in cash, cash equivalents, and restricted cash | $9,606 | $(101,455) | | Cash, cash equivalents, and restricted cash at end of period | $116,550 | $101,058 | [Notes to Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) - AlloVir is a late clinical-stage cell therapy company, with its lead product, posoleucel, in three ongoing Phase 3 trials expected to report data in 2024, following positive Phase 2 results in February 2023[38](index=38&type=chunk) - The company believes its **$202.6 million** in cash, cash equivalents, and short-term investments as of March 31, 2023, are sufficient to fund planned operations for at least twelve months, addressing going concern considerations[40](index=40&type=chunk)[44](index=44&type=chunk) - The adoption of ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326), on January 1, 2023, did not materially impact the condensed consolidated financial statements[52](index=52&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=16&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial condition and operational results, reporting a **net loss of $41.2 million** for Q1 2023, with **$202.6 million** in cash sufficient for twelve months of operations - The company's lead product, posoleucel, is in three ongoing Phase 3 registrational trials with data readouts expected in 2024, following positive Phase 2 results for BK viremia in kidney transplant patients in February 2023[89](index=89&type=chunk) Comparison of Operating Expenses (in thousands USD) | Expense Category | Three Months Ended March 31, 2023 (in thousands USD) | Three Months Ended March 31, 2022 (in thousands USD) | Change (in thousands USD) | | :--- | :--- | :--- | :--- | | Research and development | $30,718 | $29,067 | $1,651 | | General and administrative | $12,513 | $14,126 | $(1,613) | | **Total operating expenses** | **$43,231** | **$43,193** | **$38** | - As of March 31, 2023, the company held **$202.6 million** in cash, cash equivalents, and short-term investments, which management believes is sufficient to fund operations and capital expenditures for at least the next twelve months[94](index=94&type=chunk)[115](index=115&type=chunk) - Net cash used in operating activities decreased to **$32.1 million** in Q1 2023 from **$46.5 million** in Q1 2022, primarily due to the timing of changes in net operating assets and liabilities[123](index=123&type=chunk)[124](index=124&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=23&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, the company is not required to provide disclosures for this item - As a smaller reporting company, AlloVir is not required to disclose quantitative and qualitative information about market risk[134](index=134&type=chunk) [Item 4. Controls and Procedures](index=23&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2023, with no material changes to internal control over financial reporting - The company's management, including the CEO and CFO, concluded that disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2023[136](index=136&type=chunk) - No material changes in the company's internal control over financial reporting occurred during the quarter[137](index=137&type=chunk) [PART II. OTHER INFORMATION](index=25&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=25&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any material legal proceedings - As of the reporting date, the company is not a party to any material arbitration or legal proceedings[141](index=141&type=chunk) [Item 1A. Risk Factors](index=25&type=section&id=Item%201A.%20Risk%20Factors) This section outlines key risks, including dependence on posoleucel's success, high development costs, need for additional funding, and intense competition - The company's business is highly dependent on its lead product candidate, posoleucel, and its ability to complete clinical testing and obtain regulatory approval[7](index=7&type=chunk)[179](index=179&type=chunk) - As a late clinical-stage entity, the company has incurred **net losses since inception**, with an **accumulated deficit of $507.0 million** as of March 31, 2023, and anticipates significant future losses[7](index=7&type=chunk)[216](index=216&type=chunk) - Substantial additional funding is required, and an inability to raise capital could force delays, reductions, or elimination of development programs or commercialization efforts[8](index=8&type=chunk)[220](index=220&type=chunk) - The company faces substantial competition from other pharmaceutical and biotechnology companies, which could significantly impact its commercial opportunities if competitors develop more successful products[10](index=10&type=chunk)[163](index=163&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=66&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports no unregistered sales of equity securities during the period - There were no unregistered sales of equity securities during the quarter[280](index=280&type=chunk) [Item 3. Defaults Upon Senior Securities](index=66&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon senior securities - There were no defaults upon senior securities[280](index=280&type=chunk) [Item 4. Mine Safety Disclosures](index=66&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - This item is not applicable[280](index=280&type=chunk) [Item 5. Other Information](index=66&type=section&id=Item%205.%20Other%20Information) The company reports no other information for this period - There is no other information to report[280](index=280&type=chunk) [Item 6. Exhibits](index=67&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with Form 10-Q, including Sarbanes-Oxley certifications and Inline XBRL data files - Exhibits include certifications from the Principal Executive Officer and Principal Financial Officer pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002[285](index=285&type=chunk) - The report incorporates various Inline XBRL documents (Instance, Schema, Calculation, Definition, Label, Presentation) for financial data tagging[281](index=281&type=chunk)[282](index=282&type=chunk)[283](index=283&type=chunk)

Allogeneic, Off-the-Shelf, Virus-Specific T Cell Therapies in Late-Stage Development February 2023 ...

Product Development - The company is developing three innovative allogeneic virus-specific T cell (VST) therapy candidates targeting 11 different viruses, with the lead product posoleucel aimed at significantly improving outcomes for transplant patients [500]. - Posoleucel is currently being studied in three ongoing Phase 3 trials, with expected completion of enrollment by the end of 2023 and potential data readouts in 2024 [501]. - ALVR106 and ALVR107 are additional investigational VST therapies in development, targeting respiratory diseases and hepatitis B, respectively [502]. - The company has faced disruptions in clinical trials and operations due to the ongoing COVID-19 pandemic, impacting timelines and patient enrollment [511]. - The company expects to incur significant expenses and operating losses as it advances product candidates through clinical development and seeks regulatory approval [537]. Financial Performance - The company reported net losses of $168.7 million and $172.0 million for the years ended December 31, 2022 and 2021, respectively, with an accumulated deficit of $465.8 million as of December 31, 2022 [506]. - The net loss for the year ended December 31, 2022, was $168.7 million, an improvement from a net loss of $171.9 million in 2021 [527]. - Cash, cash equivalents, and short-term investments totaled $233.8 million as of December 31, 2022, expected to fund operations for at least twelve months [509]. - Net cash used in operating activities was $142.1 million for the year ended December 31, 2022, compared to $106.3 million in 2021 [543]. - Net cash provided by financing activities was $127.0 million for the year ended December 31, 2022, primarily from the issuance of common stock [546]. Expenses - The company has incurred significant operating losses primarily due to research and development activities and general administrative costs, with expectations of continued increasing expenses [507]. - Research and development expenses were $118.9 million for the year ended December 31, 2022, a decrease of $1.9 million from $120.7 million in 2021 [530]. - General and administrative expenses increased to $52.3 million in 2022 from $49.1 million in 2021, reflecting a $3.2 million increase [531]. Capital and Financing - The company has not generated any revenue from product sales and relies on capital raising through equity and debt financings to support operations [503]. - The company has received net cash proceeds of approximately $156.3 million from preferred stock sales and $292.0 million from common stock in its IPO [534]. - The relationship with ElevateBio includes shared management and support for drug development and manufacturing services, enhancing the company's operational capabilities [513]. Accounting and Compliance - The company utilizes U.S. GAAP for its consolidated financial statements, requiring estimates and judgments that may affect reported amounts of assets and liabilities [552]. - Stock-based compensation expense is recognized based on the grant date fair value, with a graded-vesting basis for performance conditions [554]. - The fair value of stock options is estimated using the Black-Scholes option-pricing model, considering factors such as expected volatility and risk-free interest rates [556]. - The company is classified as an "emerging growth company" under the JOBS Act, allowing it to delay compliance with certain accounting standards [562]. - The company will remain an emerging growth company until it meets specific revenue or market value thresholds, including total annual gross revenues of at least $1.0 billion [566]. - The company is also classified as a "smaller reporting company," with market value held by non-affiliates less than $700 million and annual revenue below $100 million [567]. - Recent accounting pronouncements that may impact financial position and results of operations are disclosed in the consolidated financial statements [568]. - As a smaller reporting company, the company is not required to disclose quantitative and qualitative disclosures about market risk [570].